<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">Cerebral embolism</z:e> may have different causes with sometimes serious consequences </plain></SENT>
<SENT sid="1" pm="."><plain>If no specific reason can be found, paradoxical embolization through a <z:mp ids='MP_0004225'>persistent foramen ovale</z:mp> (<z:mp ids='MP_0004225'>PFO</z:mp>) is increasingly as a cause of the <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This study was undertaken to ascertain whether in patients with <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> occlusion of a <z:mp ids='MP_0004225'>PFO</z:mp> with a transcatheter technique can prevent further <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral emboli</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Indications for transcatheter occlusion were based on neurological signs (ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo>), cardiovascular diagnosis, and coagulation tests </plain></SENT>
<SENT sid="4" pm="."><plain>Between August 1991 and July 1996, transcatheter occlusion of a <z:mp ids='MP_0004225'>PFO</z:mp> was performed in 28 fully anticoagulated patients (median age 37.8 [15.4-65.4] years) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean <z:mp ids='MP_0004225'>PFO</z:mp> diameter was 9.5 mm (3-17), mean duration of fluoroscopy 18.3 (8.7-43.1) min </plain></SENT>
<SENT sid="6" pm="."><plain>The Rashkind device was implanted in three patients, the Sideris buttoned device in 25 </plain></SENT>
<SENT sid="7" pm="."><plain>During the follow-up period (2-64 months; mean 13 months) renewed neurological symptoms occurred in only one patient </plain></SENT>
<SENT sid="8" pm="."><plain>Transoesophageal echocardiography excluded <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> on the implanted device or in the left atrium, and a residual <z:mp ids='MP_0004225'>PFO</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>The cause of the one neurological episode is therefore not clear </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other patients have remained free of symptoms and recurrence without anticoagulation after placement of the device </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Transcatheter occlusion of a <z:mp ids='MP_0004225'>PFO</z:mp> is a relatively simple and safe procedure </plain></SENT>
<SENT sid="12" pm="."><plain>Our results suggest that it can at least lower the incidence of further cerebral embolizations </plain></SENT>
<SENT sid="13" pm="."><plain>The clinical value of the method in comparison with anticoagulation requires further study </plain></SENT>
</text></document>